Phase 3
N=171
The POUR (Postoperative Urinary Retention) Study
Postoperative Urinary Retention
Bottom Line
View on ClinicalTrials.gov: NCT05276804 ↗Enrolled (actual)
171
Serious AEs
0.0%
Results posted
Jul 2025
Primary outcome: Primary: Number of Participants With Urinary Retention — 0; 11; 74; 63 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- Sugammadex (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Wake Forest University Health Sciences
- Primary completion
- Sep 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Urinary Retention |
0; 11; 74; 63 | — |
| SECONDARY Length of Stay (Days) |
0.0; 0.3 | — |
| SECONDARY Hospital Cost |
57954; 54970 | — |
Summary
The primary aim of this study will be to compare the rate of postoperative urinary retention between patients receiving Sugammadex and those receiving traditional reversal agents
Eligibility Criteria
Inclusion Criteria
- Over the age of 18
- Undergoing laparoscopic inguinal hernia repair at Carolinas Medical Center by attending surgeons within the Division of Gastrointestinal and Minimally Invasive Surgery
- Unilateral or bilateral inguinal hernia repair; may have concurrent umbilical hernia repair performed
- Agreeable to participation in the study
Exclusion Criteria
- Patients who are having concurrent ventral or flank hernias repaired at time of operation or are having an inguinal hernia repair along with another operation (e.g.
laparoscopic cholecystectomy)
- End-stage renal disease (Creatinine clearance less than 30)
- Neuromuscular disease
- Prior adverse reactions to Sugammadex
- Patients who do not provide consent for the study
Data sourced from ClinicalTrials.gov (NCT05276804). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.